153 related articles for article (PubMed ID: 38592164)
1. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
Daeschler D; Fugh-Berman A
Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
[TBL] [Abstract][Full Text] [Related]
2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
3. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
[No Abstract] [Full Text] [Related]
4. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
5. Pimavanserin.
Hunter NS; Anderson KC; Cox A
Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
[TBL] [Abstract][Full Text] [Related]
6. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin for the treatment of Parkinson's disease psychosis.
Chendo I; Ferreira JJ
Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
10. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
Duits JH; Ongering MS; Martens HJM; Schulte PFJ
Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin for the treatment of Parkinson's disease psychosis.
Friedman JH
Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
[TBL] [Abstract][Full Text] [Related]
12. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
13. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Norton JC; Chi-Burris K; Demos G
CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
[TBL] [Abstract][Full Text] [Related]
14. On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease Psychosis.
Pagan FL; Schulz PE; Torres-Yaghi Y; Pontone GM
CNS Drugs; 2024 May; 38(5):333-347. PubMed ID: 38587586
[TBL] [Abstract][Full Text] [Related]
15. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
16. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Hermanowicz N; Alva G; Pagan F; Espay AJ; Patel A; Madrid KC; Kremens D; Kenney J; Arquette S; Tereso G; Lopes M; Farnum C
J Manag Care Spec Pharm; 2017 Jun; 23(6-b Suppl):S2-S8. PubMed ID: 28636480
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
19. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
